Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of tofacitinib in active ankylosing spondylitis
2018-000226-58Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Tofacitinib 5 mg BID with Placebo (2 arms). Primary endpoint: ASAS20 response at Week 16. Started Apr 2018; status: completed.
02
Drugs
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2018-000226-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000226-58.